🇺🇸 FDA
Pipeline program

LY3819253

014 / ACTIV-3

Phase 3 mab completed

Quick answer

LY3819253 for Covid19 is a Phase 3 program (mab) at Vir Biotechnology with 1 ClinicalTrials.gov record(s).

Program details

Company
Vir Biotechnology
Indication
Covid19
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials